# AETHLON MEDICAL, INC. (AEMD) · Edgar & Edgarette company card

> Aethlon Medical (AEMD) saw revenue fall 100% in FY2024 to $0 million, operating margin null against a 1.2% median for surgical & medical instruments & apparatus, equity 69.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 882291 · fiscal year ended 2024-03-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AEMD) · [JSON](https://www.pops4.com/boards/company/AEMD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -2072.0%) |
| Net margin | -Infinity% |
| Operating cash flow | −$10M |
| Capital spending | $250,867 |
| Free cash flow | −$10M |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $8M |
| Total equity | $6M |
| Equity ÷ assets | 69.9% |
| Return on equity | -211.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -65.47 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Sound ship · one warning sign · operating cash flow was negative (-$7.0M in FY2026)

## Edgarette's reading

Exposure: revenue $0K (FY2024). Experience: revenue down 100.0% on the year; operating margin null, down from -2072.0%. Soundness: equity 69.9% of assets, return on equity -211.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin null against a 1.2% median; growth -100.0% against 11.6%.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-01 ([filing](https://www.sec.gov/Archives/edgar/data/882291/000168316826007542/0001683168-26-007542-index.htm))

## Recent filings

- 8-K · filed 2026-10-09 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882291/000168316826007749/0001683168-26-007749-index.htm)
- 8-K · filed 2026-10-01 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882291/000168316826007542/0001683168-26-007542-index.htm)
- 8-K · filed 2026-09-17 · 1.01 Entry into a Material Definitive Agreement; 5.01 Changes in Control of Registrant; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882291/000168316826007206/0001683168-26-007206-index.htm)
- 8-K · filed 2026-09-15 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882291/000168316826007126/0001683168-26-007126-index.htm)
- DEF 14A · filed 2026-09-01 · [filing](https://www.sec.gov/Archives/edgar/data/882291/000168316826006844/0001683168-26-006844-index.htm)
- 8-K · filed 2026-08-31 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/882291/000168316826006815/0001683168-26-006815-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000882291.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=882291

## Cite

POPS4, Edgar & Edgarette: AETHLON MEDICAL, INC. (AEMD) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/AEMD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2026, which reports no revenue; the revenue figures and the range here are from FY2024, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.